Status
Conditions
Treatments
About
To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT/3TC.
Full description
AZT-experienced patients are randomized to receive MK-639/AZT/3TC or MK-639 alone or AZT/3TC. Additionally, patients who have received < 6 months of AZT or who are intolerant but received prior 3TC or who require concomitant rifampin therapy may receive open-label MK-639.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Concurrent Medication:
Allowed for all patients:
Allowed for open-label study patients:
Patients must have:
NOTE:
Prior Medication:
Required for blinded study patients:
Required for open-label study patients:
Allowed for open-label study patients:
Exclusion Criteria
Concurrent Medication:
Excluded in all patients:
Excluded in blinded study patients:
Excluded in open-label study patients:
Prior Medication:
Excluded in all patients:
Excluded in blinded study patients:
Excluded in open-label study patients:
3TC within 30 days prior to study entry.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal